A5015539158- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Neutropenia and Cancer Infections
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Antifungal resistance and susceptibility
- CNS Lymphoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Ovarian cancer diagnosis and treatment
- Cancer therapeutics and mechanisms
Ospedale Policlinico San Martino
2016-2025
University of Genoa
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2016
Fondazione Intergruppo Italiano Linfomi Onlus
2016
Fondazione Gimema Onlus
2008-2011
Martin University
2009
Istituto di Ematologia di Bologna
2009
University of Bologna
2009
Alleanza Contro il Cancro
1997-2005
ISI Foundation
2002
Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), 15). The median age was 42 years (range, 18-66 years); 23 were in remission, 27 had active disease, and 10 receiving a second allograft. Graft-versus-host disease (GVHD)...
Abstract Background Immunocompromised patients show prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swabs. We report a case persistence viable SARS-CoV-2 associated with clinical relapses disease 2019 (COVID-19) patient mantle cell lymphoma who underwent treatment rituximab, bendamustine, cytarabine consequent lymphopenia and hypogammaglobulinemia. Methods Nasopharyngeal swabs blood samples were tested for by real-time polymerase chain...
Abstract The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a histone-deacetylase inhibitor, showed promising activity in relapsed PTCLs; first line, Romidepsin was added CHOP. We designed study combining romidepsin CHOEP as induction before HDT auto-SCT (PTCL-NOS, AITL/THF, ALK-ALCL), aged 18–65 years. A phase...
Trials to determine the effect of thalidomide in patients with Myelofibrosis Myeloid Metaplasia (MMM) have produced inconclusive results due different criteria for response and heterogeneous study participants. We undertook a pooled-analysis assess effects such treatment on larger series cases uniform assessment response. used updated data 62 individual from 5 phase II trials that evaluated therapy MMM patients. Responsewas judged disease parameters, improvement Dupriez risk categories 6...
To assess potential benefits with thalidomide incorporated into double autologous stem-cell transplantation (ASCT) for younger patients newly diagnosed multiple myeloma (MM).One hundred thirty-five who received from induction until the second ASCT were retrospectively analyzed in comparison an equal number of pair mates treated not including thalidomide.On intention-to-treat basis, addition to effected a significant improvement rate (68% v 49%; P = .001) and duration (62% 33% at 4 years; <...
We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) NPM (nucleophosmin) gene mutations WT1 (Wilms' tumor) BAALC (brain acute leukemia, cytoplasmic) expression in 100 consecutive patients with intermediate poor cytogenetic risk de novo myeloid leukemia (AML) receiving conventional anthracycline–AraC based therapy. observed a strict relationship between unfavorable karyotype >1000 (p = 0.0001). Multivariate analysis 81 revealed that younger age...
Abstract Background Immunocompromised patients show prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs. We report a case persistence viable associated with clinical relapses COVID-19 lymphoma patient. Methods Nasopharyngeal swabs and blood samples were tested for by Real time-PCR (RT-PCR). On five positive swabs, we performed viral culture next generation sequencing. analysed the patients’ adaptive innate immunity to characterize T NK cell subsets. Findings RT-PCR on remained cycle...
Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell (MCL) remains unclear. Here, we report a comprehensive NGS-based analysis of the M-CH mutational landscape at baseline and follow-up patients enrolled Fondazione Italiana Linfomi (FIL) MCL0208 phase 3 trial (NCT02354313), evaluating lenalidomide maintenance versus observation after chemoimmunotherapy autologous stem transplantation (ASCT) untreated...
We analysed interim metabolic response (iPET) in a subset of Follicular Lymphoma (FL) patients enrolled the randomized FOLL12 trial. Grade 1-3a FL with an iPET performed between cycles 4 and 5 first-line immunochemotherapy (ICT) were included; PET scan had to be centrally reviewed for definition Deauville Score (DS) considered positive DS4-5. Overall 123 out 211 available central review. Of these, 43% older than 60, 33% high-risk FLIPI2, 47% received R-Bendamustine as induction regimen....
Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, cytokine regulatory properties recently it has been used successfully in multiple myeloma. Here, we report our experience 10 MMM patients treated Thal. Patients agnogenic an early phase the disease obtained significant benefits from therapy remain transfusion‐free. In contrast, all secondary failed to respond....
Abstract: Objective: In this prospective study we evaluate the effects of high‐dose recombinant human erythropoietin (rHuEPO) on quality life (QOL) and brain function in patients with low‐risk myelodysplastic syndromes (MDS) (<10% marrow blasts). Preliminary data are reported. Methods: Eleven consecutive were given rHuEPO (40 000 IU two times a week) for 12 wk. Responsive continued 40 IU/wk further Changes QOL assessed by Functional Assessment Cancer Therapy‐Anemia (FACT‐An) self‐report....
The mutations of NPM1 and FLT3-ITD represent the most frequent genetic aberration in acute myeloid leukemia. Indeed, presence an mutation reduces negative prognostic impact patients treated with conventional “3+7” induction. However, little information is available on their role intensified regimens. Here, we investigated efficacy a fludarabine, high-dose cytarabine idarubicin induction (FLAI) 149 consecutive fit AML (median age 52) carrying and/or mutation, from 2008 to 2018....
Abstract Current treatments for non‐Hodgkin lymphomas are not optimally effective. Among new agents, bortezomib seems to play a pivotal role in the regulation of several cell pathways involved development lymphomas. After results were obtained with clinical trials, we aimed observe treatment everyday practice. We performed multicenter retrospective analysis assess efficacy heavily pretreated (median number previous therapies 4, range 2–6) lymphoma patients an off‐label setting. Bortezomib...